A COMPREHENSIVE REVIEW ON DEVELOPMENT AND VALIDATION OF ANALYTICAL METHODS FOR ANTIDIABETIC PHYTOCONSTITUENT EVALUATION IN WITHANIA COAGULANS-LOADED HERBAL GUMMIES

Ekta Ram*, Subhashree Sushantika Naik

Withania coagulans is a medicinal plant traditionally used in South Asia, and its bioactive phytoconstituents, particularly withanolides and flavonoids, have demonstrated considerable antidiabetic potential. However, the translation of these benefits into standardized, patient-friendly oral dosage forms such as herbal gummies remains poorly investigated. The present systematic review was designed to critically synthesize and evaluate the existing evidence on the development and analytical validation of W. coagulans-loaded gummy formulations for antidiabetic applications. Our methodology followed the PRISMA guidelines, and we conducted a comprehensive literature search across multiple scientific databases. We included original peer-reviewed studies that addressed the phytochemical characterization of W. coagulans, its antidiabetic evaluation, or the formulation of herbal gummies, and we excluded studies on other Withania species or non-oral dosage forms. Two independent reviewers screened the records, extracted data on extraction methods, analytical validation parameters, formulation ingredients, and antidiabetic outcomes, and assessed the methodological quality of the included studies. The results revealed a pronounced disconnect in the literature. While substantial evidence supports the antidiabetic activity of W. coagulans extracts through enzyme inhibition and antioxidant assays, we found no validated analytical methods for quantifying key phytoconstituents within a gummy matrix. Furthermore, existing formulation studies focused on other herbs, and no standardized protocol for incorporating W. coagulans while maintaining phytoconstituent stability was identified. The review therefore highlights critical gaps, including the absence of stability-indicating chromatographic methods for complex gummy matrices and the lack of any in vivo or clinical translation studies. We conclude that future research must prioritize the development of validated analytical protocols, systematic formulation optimization, and controlled preclinical trials to bridge the gap between raw plant characterization and a ready-to-market, evidence-based antidiabetic nutraceutical.